<DOC>
	<DOCNO>NCT02806141</DOCNO>
	<brief_summary>This study plan compare clinical efficacy safety aerosolize plus intravenous colistin vs. intravenous colistin adjunctive therapy treatment ventilator-associated pneumonia ( VAP ) due pandrugs-resistant ( PDR ) Acinetobacter baumannii neonate .</brief_summary>
	<brief_title>Aerosolized Plus Intravenous vs. Intravenous Colistin VAP Due Pandrugs-resistant A. Baumannii Neonates</brief_title>
	<detailed_description>This study evaluate neonate VAP due PDR-Acinetobacter baumannii receive aerosolize plus intravenous colistin compare intravenous colistin adjunctive therapy . The efficacy safety study evaluate .</detailed_description>
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>Pneumonia</mesh_term>
	<mesh_term>Pneumonia , Ventilator-Associated</mesh_term>
	<mesh_term>Colistin</mesh_term>
	<criteria>Neonates admit neonatal intensive care unit , Hat Yai Hospital study period . Neonates complicate VAP due PDRAcinetobacter baumannii susceptible colistin ( minimal inhibitory concentration ( MIC ) &lt; 2 mcg/dL ) . Neonates major anomaly chromosomal abnormality . Neonates receive colistin prior 7 day prior study . Neonates significant renal dysfunction define serum creatinine ( SCr ) &gt; 1.5 mg/dL decrease urine output &lt; 1 mL/kg/h ;</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>30 Days</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Aerosolized colistin</keyword>
	<keyword>Intravenous colistin</keyword>
</DOC>